Pierre Bédossa

机构：Université Sorbonne Paris Nord, Interdisciplinary University of Paris, Newcastle University, Régie Autonome des Transports Parisiens (France) · ORCID：0000-0002-8487-7322

发表论文 889 篇 · 总被引 72715 次 · h-index 122

代表论文

• Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial (2024 · ˜The œLancet. Gastroenterology & hepatology · 被引 101)
• Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial (2025 · The Lancet · 被引 59)
• ACBP/DBI neutralization for the experimental treatment of fatty liver disease (2024 · Cell Death and Differentiation · 被引 17)
• Consensus position statements for the standardized application of histological grading and staging systems in MASH clinical trials (2025 · Journal of Hepatology · 被引 12)
• Altered liver sinusoidal endothelial cells in MASLD and their evolution following lanifibranor treatment (2025 · JHEP Reports · 被引 9)
• Metabolic and hepatic phenotypes in sarcopenic obesity and impact of bariatric surgery (2024 · Clinical Nutrition · 被引 8)